Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

enics announced that a group of

private investors based in Belgium had together acquired an 8% stake in

the Company. This stake was purchased from Biggar Limited, a charitable

foundation that is ThromboGenics' largest single shareholder. Biggar

now holds a 9.8% stake in ThromboGenics, and has informed the Company

that it intends to remain an important shareholder in ThromboGenics for

the long term.

- ThromboGenics shares entered the Bel Mid Index on 1 October

2008, following the quarterly review of the Belgian indices by

Euronext. The elevation of ThromboGenics to the Bel Mid Index reflects

the significant progress that the Company has made since its IPO in

2006.

Corporate Update

- On 1 September, Patrik De Haes, MD, formerly the Company's

Chief Operating Officer, was appointed to succeed Professor Desire

Collen as the Company's new Chief Executive Officer. Dr. De Haes will

be proposed to become a member of the Board of Directors of

ThromboGenics at the next General Meeting. In the meantime, he will be

invited to participate in Board meetings.

ThromboGenics will continue to benefit from Professor Collen's significant scientific and drug discovery knowledge. Professor Collen will remain Chairman of ThromboGenics' Board of Directors.

Pipeline Update

Microplasmin in Eye Disease

ThromboGenics is working to finalise its Phase III clinical trial program for microplasmin in the treatment of back of the eye disease, following a successful End of Phase II meeting with the FDA. The initial indication planned for the program is the nonsurgical resolution of vitreomacular adhesion. Two placebo controlled trials are planned, one in the U.S. and one combined European and North American trial. Together it is anticipated that the two trials will recruit a total of approximately 640 patients, with the first trial ex
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Calif. , Nov. 24, 2014   Veracyte, Inc. ... Bonnie H. Anderson , president and chief executive officer, will ... 26 th Annual Healthcare Conference on Tuesday, December 2, ... . The live audio webcast and subsequent ... http://investor.veracyte.com . Please connect to the website at least 15 ...
(Date:11/24/2014)... 2014  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden Corporation ... the United States District Court for the Northern ... On November 21, 2014 the Markman ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Prominent ... investors will gather on December 3rd at Genetic ... Conferences series. GeneticRx will take place at the ... School and will discuss the present and future ... exon skipping, and gene editing—as well as the ...
(Date:11/22/2014)... Rapids, MI (PRWEB) November 22, 2014 ... opportunity to simulate the proper management of life-like ... and test lung devices . Grand Rapids-based, Michigan ... plans to donate two of the respiratory simulation ... to $15,000 each. Grand Valley and Muskegon Community ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3
... Sept. 16 Metamark Genetics, Inc., a privately held ... optimize cancer care, announced today the appointment ... Dr. Blume-Jensen joins Metamark with over 20 ... discovery. From 2001 to 2008 Dr. Blume-Jensen was department ...
... Sept. 15 CryoLife, Inc. (NYSE: ... processing company, announced today that it will participate in the ... in New York City. D. Ashley Lee, executive ... CryoLife, Inc., will present a corporate overview on Tuesday, September ...
... 14, 2010 -- As industries and consumers increasingly seek ... Department of Energy,s Oak Ridge National Laboratory is providing ... A research team led by ORNL,s Nina Balke, ... type of scanning probe microscopy called electrochemical strain microscopy ...
Cached Biology Technology:Metamark Genetics, Inc. Announces New Chief Scientific Officer 2CryoLife to Present at UBS Global Life Sciences Conference 2ORNL scientists reveal battery behavior at the nanoscale 2
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/10/2014)... detergent pods began appearing on U.S. store shelves in ... numbers ever since. The small packets can be tossed ... out a liquid or powder. The convenience, though, has ... study from researchers at Nationwide Children,s Hospital found that ... reports of 17,230 children younger than 6 years of ...
(Date:11/7/2014)... Florida , November 6, 2014 ... authentication for better mobile security revolutionizing online transactions.  Companies in ... Alibaba Holdings Ltd. (NYSE: BABA ), Google Inc. ... MSFT ), eBay Inc. (NASDAQ: EBAY ) and ... NXTD and NXTDW), a biometric authentication company focused ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... $50 billion in manufactured goods last year, according to ... $2.6 trillion. By 2011, over $15 billion in nano-enabled ... $3 billion in 2006. And industry experts project that ... consumer food products by 2010. Yet, ...
... Artificial teeth and crowns made of ceramic material are ... but that may change because of a technique that ... Oak Ridge National Laboratorys Materials Science and Technology Division has ... ceramics alters the surface structure. Nowadays, cracks begin at the ...
... Brussels & Leuven, Belgium As the most common ... carries enormous implications for our ageing society. It is ... peptide (A -peptide) protofibrils. Until now, the conditions under ... to the disease remained unknown. VIB researchers have now ...
Cached Biology News:FDLI, PEN co-sponsor major conference on nanotechnology 2FDLI, PEN co-sponsor major conference on nanotechnology 3Story tips from the Department of Energy's Oak Ridge National Laboratory, December 2007 2Story tips from the Department of Energy's Oak Ridge National Laboratory, December 2007 3Lipids in the brain an important factor for Alzheimer's disease? 2
RABBIT ANTI HALOPERIDOL...
Form: Ready to use Applications: Western Blot, ELISA...
... Analyzer for General Chemistries, Specialty Chemistries, QC, Reagent Development, Pharmaceutical Development, Physician Owned Labs, Drugs ... user-selectable wavelengths. ... ... ...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
Biology Products: